Quarterly Report · 10-Q
Verastem, Inc.
VSTMNASDAQEQUITYCurrent
Quarterly Report
Company context
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
Current securities
Recent company filings
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗